Perspective Therapeutics (NYSE:CATX) lost ~22% in the premarket on Thursday after the cancer drug developer posted results from its ongoing Phase 1/2a clinical trial for its radiopharmaceutical ...
Short interest in Perspective Therapeutics Inc (AMEX:CATX) decreased during the last reporting period, falling from 9.59M to 7.88M. This put 14.23% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback